Recent Updates — MBOT

Microbot Medical Inc. entered into a three-year exclusive commercial distribution agreement with Medtechnica Ltd., authorizing the distributor to market and sell the LIBERTY Endovascular Robotic System throughout Israel. The company received regulatory approval from the Israeli Ministry of Health’s AMAR Division in May 2026 and anticipates initial orders during the fourth quarter of 2026. This partnership supports Microbot's international expansion strategy as it prepares for potential market entry outside the U.S. Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology.

Microbot Medical Inc. filed its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, announcing significant operational growth. Revenue increased by more than 100% compared to the first quarter of 2026, driven by repeat orders and expanded utilization following the Full Market Release in April. The company added new health systems in Massachusetts, North Carolina, Michigan, and Pennsylvania, expanding its sales footprint from four to eight territories. It also entered agreements with Lovell Government Services Inc. for federal healthcare access and Sanmina for a second manufacturing site. Additionally, Israel granted marketing clearance for the LIBERTY System, marking the first regulatory approval outside the U.S. Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology.